Table 1 Characteristics of included studies.

From: Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis

Study ID

Study Design

Trial Registration Number

Population

Intervention vs Comparison

Outcome

Bussel 2015

Multicenter (22 centers in the USA, UK, Canada, Spain, France, and the Netherlands), double-blind, RCT.

NCT00908037

Patients aged 1–17years, with a diagnosis of ITP(duration of ≥6 months) in accordance with existing guidelines, had a platelet counts <30 × 109/L.

Eltrombopag vs Placebo

①②③④⑤⑥⑦

Grainger 2015

Multicenter (38 centers in 12 countries: Argentina, Czech Republic, Germany, Hong Kong, Isreal, Italy, Russia, Spain, Taiwan, Thailand, UK, and USA), double-blind, RCT.

NCT01520909

Patients aged 1–17years, with a diagnosis of chronic ITP (duration of >12months) in accordance with the IWG guidelines, had a platelet counts <30 × 109/L.

Eltrombopag vs Placebo

①②③④⑤⑥⑦

Bussel 2011

Multicenter (10 centers in the USA, Spain, and Australia), double-blind, RCT.

NCT00515203

Patients aged 1–17years, with a diagnosis with ITP(duration of ≥6 months) according to American Society of Hematology guidelines, had a platelet <30 × 109/L.

Romiplostim vs Placebo

①③④⑤⑥⑦

Tarantino 2016

Multicenter (27 centers in the USA, Canada and Australia), double-blind, RCT.

NCT01444417

Patients aged 1–18 years with a diagnosis of primary ITP(duration of ≥6 months), had a platelet <0 × 109/L.

Romiplostim vs Placebo

①②③④⑤⑥⑦

Elalfy 2011

Single-center (Egypt), single-blind, RCT.

NA

Patients aged 2.5–16 years with a diagnosis of ITP(duration of >12 months) according to American Society of Hematology guidelines, had a platelet <20 × 109/L.

Romiplostim vs Placebo

①⑤⑥⑦

  1. ①Overall platelet response; ②Durable platelet response; ③Clinically significant bleeding; ④All bleeding events; ⑤Rescue medication; ⑥Adverse events; ⑦Serious adverse events; NA: not applicable.
Back to article page